Relmada Therapeutics (RLMD) Accumulated Depreciation & Amortization (2015 - 2021)

Relmada Therapeutics (RLMD) has 7 years of Accumulated Depreciation & Amortization data on file, last reported at $1258.0 in Q3 2021.

• Accumulated Depreciation & Amortization for Q3 2021 came in at $1258.0, down 57.05% year-over-year; the trailing twelve-month figure through Sep 2021 was $1258.0 (down 57.05% YoY), and the FY2020 annual result was $15442.0, up 32.1% from the prior year.
• Accumulated Depreciation & Amortization declined to $1258.0 in Q3 2021 per RLMD's latest filing, from $1.3 million in the prior quarter.
• Over five years, Accumulated Depreciation & Amortization peaked at $2.1 million in Q2 2020 and troughed at $1258.0 in Q3 2021.
• A 5-year average of $192003.9 and a median of $8402.0 in 2019 frame the typical range for Accumulated Depreciation & Amortization.
• The sharpest annual moves came in 2018 and 2020: Accumulated Depreciation & Amortization slumped 97.16% in 2018, then soared 22028.56% in 2020.
• A 5-year view of Accumulated Depreciation & Amortization shows it stood at $3124.0 in 2017, then soared by 134.51% to $7326.0 in 2018, then surged by 59.57% to $11690.0 in 2019, then jumped by 32.1% to $15442.0 in 2020, then sank by 91.85% to $1258.0 in 2021.
• Business Quant data shows RLMD's Accumulated Depreciation & Amortization at $1258.0 in Q3 2021, $1.3 million in Q2 2021, and $16248.0 in Q1 2021.